GSK's Lung Cancer Drug Nelkarmi Approved by FDA
nashnova research
GSK's lung cancer drug Nelkarmi has won accelerated FDA approval for ALK-positive advanced non-small cell lung cancer — the second oncology drug to reach market from GSK's $10.6 billion Nuvalent acquisition, with analysts projecting annual sales of roughly $1 billion by 2032.
What does this drug treat, and how was it approved?
Nelkarmi targets locally advanced or metastatic non-small cell lung cancer driven by ALK gene mutations — a genetic abnormality that causes uncontrolled tumor growth, found in roughly 3%–5% of NSCLC cases.
It is indicated for patients whose disease progressed after first-generation ALK inhibitors. This means → the drug fills the gap after existing therapies fail, not the first-line slot.
The FDA granted approval through its accelerated pathway, based on significant anti-tumor activity in early-stage trials. In plain terms = the agency saw a strong enough efficacy signal to let the drug reach patients now, with full data to follow.
The side-effect profile is comparable to existing ALK inhibitors; a confirmatory Phase III trial is still underway.
Where did this drug come from?
Nelkarmi came from GSK's $10.6 billion acquisition of U.S. biotech Nuvalent earlier this year.
The same deal delivered another oncology drug, Jideytro, which won U.S. approval in July. This means → one acquisition has produced two approved drugs within six months — the commercial payoff is materializing fast.
Both approvals are flagship results of new CEO Luke Miels's strategy to expand GSK's oncology portfolio.
Where does GSK's oncology strategy stand now?
Hesham Abdullah, GSK's head of oncology R&D, said: "I think we are making significant progress across our oncology portfolio."
The company is building a lung cancer product line while advancing pipeline candidates in blood cancers and gastrointestinal tumors. This reflects a multi-indication bet, not a single-disease wager.
What are analysts expecting?
Ahead of the approval, Jefferies analyst Michael Leuchten noted the drug carries "meaningful upside potential" extending into 2030 and beyond.
Bloomberg consensus forecasts project Nelkarmi's annual sales reaching roughly $1 billion by 2032.
The Phase III data readout will be the pivotal checkpoint. In plain terms = the current sales estimate rests on early-stage evidence; if the Phase III falls short, that number will need to be recalculated.
市场有风险,内容仅供研究参考,不构成投资建议。
